Larimar Therapeutics Inc
NASDAQ:LRMR

Watchlist Manager
Larimar Therapeutics Inc Logo
Larimar Therapeutics Inc
NASDAQ:LRMR
Watchlist
Price: 3.26 USD -4.4%
Market Cap: 279m USD

Relative Value

There is not enough data to reliably calculate the relative value of LRMR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LRMR Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-4
Industry
24.2
Forward
-1.6
vs History
vs Industry
Median 3Y
-6
Median 5Y
-4.8
Industry
23
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-4.7
Industry
25.5
vs History
50
vs Industry
65
Median 3Y
1.9
Median 5Y
2
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
vs History
vs Industry
20
Median 3Y
-1.7
Median 5Y
-1.7
Industry
6.1
Forward
-0.7
vs History
vs Industry
18
Median 3Y
-1.7
Median 5Y
-1.7
Industry
6.6
Forward
-0.7
vs History
vs Industry
21
Median 3Y
-2.2
Median 5Y
-2
Industry
8.8
vs History
vs Industry
17
Median 3Y
-2.2
Median 5Y
-2
Industry
6.8
vs History
6
vs Industry
14
Median 3Y
13.1
Median 5Y
12.8
Industry
5.7

Multiples Across Competitors

LRMR Competitors Multiples
Larimar Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Larimar Therapeutics Inc
NASDAQ:LRMR
279m USD 0 -2.1 -0.7 -0.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 170 980.7 -162 409.6 -197 217.1 -194 966.6
US
Abbvie Inc
NYSE:ABBV
380B USD 6.4 161.8 15.8 22.4
US
Amgen Inc
NASDAQ:AMGN
177B USD 4.9 25.3 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
152.2B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.4B USD 9.5 30.4 22.2 23.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.7 -526.1 -572.9 -557.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 19 12.8 16
NL
argenx SE
XBRU:ARGX
42.5B EUR 13.7 32.2 55.3 56.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48B USD 14.7 1 085.6 148.6 180.2
P/S Multiple
Revenue Growth P/S to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average P/S: 3 417 310.6
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 170 980.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
1
US
E
Epizyme Inc
F:EPE
2 061.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.7
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average P/E: 173.8
Negative Multiple: -2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 409.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.8
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
10%
1.7
AU
CSL Ltd
ASX:CSL
19
11%
1.7
NL
argenx SE
XBRU:ARGX
32.2
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 085.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average EV/EBITDA: 37.7
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.8
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.3
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
148.6
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average EV/EBIT: 43.5
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 966.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
56.8
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
180.2
N/A N/A